Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations

Next Previous
X
Search
Trial Profile

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms HOVON 141 CLL/ VIsion

    • Most Recent Events

    • 15 Jun 2023 Results identifying functional biomarkers at baseline that predict MRD status at month 15 in the patients enrolled in this study, presented at the 28th Congress of the European Haematology Association
    • 15 Jun 2023 Results analyzing the relation between LN-mediated signaling, and the potential to induce venetoclax resistance presented at the 28th Congress of the European Haematology Association
    • 15 Jun 2023 Results analyzing long-term clinical outcome and MRD-kinetics with a median follow up of 50.8 months for patients enrolled in the VISION trial presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top